Ipratropium (Ipratropium Bromide)

Subscribe to Selected New Research on Ipratropium

848 relevant articles (135 outcomes, 192 trials/studies) found for this Drug

Description: A muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic.

Also Known As:

Ipratropium Bromide; (endo,syn)-(+-)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo(3.2.1)octane; Atrovent; Ipratropium Bromide, (endo,anti)-Isomer; Ipratropium Bromide, (exo,syn)-Isomer; Ipratropium Bromide, endo-Isomer; Itrop; Sch-1000; Sch-1178; N Isopropylatropine; Sch 1000; Sch 1178; Sch1000; Sch1178; N-Isopropylatropine; 8-Azoniabicyclo(3.2.1)octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, (endo,syn)-(+-)-

Relationship Network

Drug Context: Research Results

Experts

1.	Kalberg, Christopher: 3 articles (01/2008 - 01/2004)
2.	Emmett, Amanda: 3 articles (01/2008 - 01/2004)
3.	Knobil, Katharine: 3 articles (01/2008 - 01/2004)
4.	Muhammad, J: 2 articles (01/2006 - 01/2006)
5.	Appleton, S: 2 articles (01/2006 - 01/2006)
6.	Lasserson, T J: 2 articles (01/2006 - 01/2006)
7.	Smith, B: 2 articles (01/2006 - 01/2006)
8.	Jones, T: 2 articles (01/2006 - 01/2006)
9.	Pilotto, L: 2 articles (01/2006 - 01/2006)
10.	Adams, R: 2 articles (01/2006 - 01/2006)

Related Diseases

1.	Chronic Obstructive Pulmonary Disease (COPD) 01/29/1996 - "These data suggest that the availability of a high-dose ipratropium bromide solution offers a safe and effective means of producing prolonged bronchodilation in patients with COPD." 01/01/2000 - "[Is nebulized ipratropium bromide effective in the treatment of exacerbations of chronic obstructive pulmonary disease?]" 05/01/1989 - "Inhaled ipratropium bromide (IPR) is effective in the management of COPD. " 11/14/1986 - "Single-agent studies have shown ipratropium to be both safe and effective in COPD. " 01/29/1996 - "These results show that ipratropium bromide, given by nebulization, is safe and effective in the outpatient treatment of COPD." Order ALL the reference details at left...
2.	Asthma (Bronchial Asthma) 07/01/1995 - "PURPOSE: To determine whether inhaled ipratropium bromide provides an additive, clinically important improvement in children with acute asthma who are being treated with beta 2-agonists. " 06/01/2000 - "We designed a larger, double-blind, randomized, prospective trial to test our hypothesis that patients with acute asthma given combination high dose therapy with ipratropium bromide (IB) and beta(2)-agonists will have greater improvement in pulmonary function and fewer hospital admissions than those given beta(2)-agonists alone. " 06/01/2003 - "High and repetitive doses of ipratropium bromide in combination with beta(2)-agonists are indicated as first line treatment of severe acute asthma. " 06/01/2002 - "(2) The use of single-dose protocols of ipratropium bromide with beta(2)-agonist treatment produced, particularly in children with more severe acute asthma, a modest improvement in pulmonary function without reduction in hospital admissions; in adults, the data showed a similar increase in pulmonary function with an approximately 35% reduction in the hospital admission rate. " 01/01/1992 - "Therefore, ipratropium bromide offers bronchodilation and protection against a variety of stimuli and should more often be considered as an effective and safe drug for asthma treatment." Order ALL the reference details at left...
3.	Rhinitis 04/01/1987 - "It is concluded that intranasal ipratropium is effective in the treatment of watery rhinorrhea in perennial nonallergic rhinitis and that 320 micrograms a day is sufficient in most patients." 04/01/1987 - "The aim of the present study was to test the efficacy of the topically active cholinoceptor antagonist, ipratropium, in the treatment of rhinorrhea in perennial nonallergic rhinitis, with special reference to identification of subgroups of responders and increased efficacy from high-dose therapy. " 06/01/1992 - "We speculate that ipratropium bromide may prove beneficial for the treatment of rhinorrhea in perennial rhinitis. " 05/01/1995 - "The purpose of the present trial was to study the safety and efficacy of a new isotonic aqueous ipratropium bromide nasal spray pump, specifically in patients with perennial nonallergic rhinitis. " 12/01/1979 - "Intranasal ipratropium: a new treatment for perennial rhinitis." Order ALL the reference details at left...
4.	Chronic Bronchitis 07/01/1976 - "[A comparative trial of bronchodilator effects of fenoteral and sch 1000 in chronic bronchitis (author's transl)]" 01/01/1998 - "The highest atrovent efficacy was recorded in patients with chronic bronchitis of smokers and chronic bronchitis in tracheobronchial diskinesia. " 01/29/1996 - "Ipratropium bromide has become primary therapy for the treatment of adults with chronic bronchitis, but its use in children has been limited. " 05/01/1994 - "Whether nebulized ipratropium bromide is of benefit to mechanically ventilated patients with chronic bronchitis is not well defined. " 01/01/1985 - "We conclude that ipratropium bromide should be inhaled in high doses (0.2 mg) by hypersecretory patients with chronic bronchitis to improve mucociliary transport." Order ALL the reference details at left...
5.	Bronchiolitis 10/01/1997 - "Efficacy of ipratropium bromide by metered dose aerosol and aerochamber in acute paediatric bronchiolitis." 01/01/1995 - "As ipratropium bromide appears to be a more effective bronchodilator drug than beta 2-stimulants in the first year of life, a study was set up to investigate its possible role in bronchiolitis. " 11/01/1983 - "In a double blind randomised trial, we found no evidence that nebulised ipratropium bromide was of clinical benefit in acute bronchiolitis." 11/01/1999 - "Nebulised ipratropium bromide and bronchiolitis." 01/29/1996 - "Ipratropium bromide can be safely used in the management of acute bronchiolitis, recognizing that most infants do not appear to respond to any bronchodilator medication. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Albuterol (Salbutamol)
2.	Ipratropium (Ipratropium Bromide)
3.	Fenoterol
4.	tiotropium (Spiriva)
5.	salmeterol (Serevent)
6.	Cromolyn Sodium (Cromoglicic Acid)
7.	Theophylline (Theon)
8.	formoterol (Oxis)
9.	Bronchodilator Agents (Bronchodilators)
10.	Beclomethasone (Beclometasone)

Related Therapies and Procedures

1.	Nebulizers and Vaporizers (Inhaler)
2.	Metered Dose Inhalers (Metered Dose Inhaler)
3.	Length of Stay
4.	Gamma Cameras (Gamma Camera)
5.	Mechanical Ventilators (Ventilator)

Best Treatments:
Research Summary Report
on Chronic Obstructive Pulmonary Disease

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 859 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>